Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.
Article
PubMed
Google Scholar
Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725–41. https://doi.org/10.1038/s41571-020-0413-z.
Article
PubMed
Google Scholar
Jackson SE, Chester JD. Personalised cancer medicine. Int J Cancer. 2015;137(2):262–6. https://doi.org/10.1002/ijc.28940.
Article
CAS
PubMed
Google Scholar
Peng Q, Li K, Sacks SH, Zhou W. The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses. Inflamm Allergy Drug Targets. 2009;8(3):236–46. https://doi.org/10.2174/187152809788681038.
Article
CAS
PubMed
Google Scholar
Ward PA. The harmful role of c5a on innate immunity in sepsis. J Innate Immun. 2010;2(5):439–45. https://doi.org/10.1159/000317194.
Article
CAS
PubMed
PubMed Central
Google Scholar
Karasu E, Demmelmaier J, Kellermann S, Holzmann K, Köhl J, Schmidt CQ, et al. Complement C5a induces pro-inflammatory microvesicle shedding in severely injured patients. Front Immunol. 2020;11:1789. https://doi.org/10.3389/fimmu.2020.01789.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lee H, Whitfeld PL, Mackay CR. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol Cell Biol. 2008;86(2):153–60. https://doi.org/10.1038/sj.icb.7100166.
Article
CAS
PubMed
Google Scholar
Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum. 1988;31(5):632–41. https://doi.org/10.1002/art.1780310508.
Article
CAS
PubMed
Google Scholar
Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol. 2003;171(10):5514–20. https://doi.org/10.4049/jimmunol.171.10.5514.
Article
CAS
PubMed
Google Scholar
Huber-Lang MS, Younkin EM, Sarma JV, McGuire SR, Lu KT, Guo RF, et al. Complement-induced impairment of innate immunity during sepsis. J Immunol. 2002;169(6):3223–31. https://doi.org/10.4049/jimmunol.169.6.3223.
Article
CAS
PubMed
Google Scholar
Sarma VJ, Huber-Lang M, Ward PA. Complement in lung disease. Autoimmunity. 2006;39(5):387–94. https://doi.org/10.1080/08916930600739456.
Article
CAS
PubMed
Google Scholar
Ajona D, Zandueta C, Corrales L, Moreno H, Pajares MJ, Ortiz-Espinosa S, et al. Blockade of the complement C5a/C5aR1 Axis impairs lung Cancer bone metastasis by CXCL16-mediated effects. Am J Respir Crit Care Med. 2018;197(9):1164–76. https://doi.org/10.1164/rccm.201703-0660OC.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhao C, Li Y, Qiu W, He F, Zhang W, Zhao D, et al. C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation. Oncogene. 2018;37(35):4821–37. https://doi.org/10.1038/s41388-018-0298-9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gu J, Ding JY, Lu CL, Lin ZW, Chu YW, Zhao GY, et al. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer. 2013;81(2):259–65. https://doi.org/10.1016/j.lungcan.2013.04.020.
Article
PubMed
Google Scholar
Kaida T, Nitta H, Kitano Y, Yamamura K, Arima K, Izumi D, et al. C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA. Oncotarget. 2016;7(51):84798–809. https://doi.org/10.18632/oncotarget.12656.
Article
PubMed
PubMed Central
Google Scholar
Nitta H, Shimose T, Emi Y, Imamura T, Ohnishi K, Kusumoto T, et al. Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes. Med Oncol. 2016;33(11):118. https://doi.org/10.1007/s12032-016-0834-9.
Article
CAS
PubMed
Google Scholar
Hu WH, Hu Z, Shen X, Dong LY, Zhou WZ, Yu XX. C5a receptor enhances hepatocellular carcinoma cell invasiveness via activating ERK1/2-mediated epithelial-mesenchymal transition. Exp Mol Pathol. 2016;100(1):101–8. https://doi.org/10.1016/j.yexmp.2015.10.001.
Article
CAS
PubMed
Google Scholar
Wada Y, Maeda Y, Kubo T, Kikuchi K, Eto M, Imamura T. C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy. Oncol Lett. 2016;12(5):3995–4000. https://doi.org/10.3892/ol.2016.5137.
Article
CAS
PubMed
PubMed Central
Google Scholar
Imamura R, Kitagawa S, Kubo T, Irie A, Kariu T, Yoneda M, et al. Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a. Prostate. 2021;81(3):147–56. https://doi.org/10.1002/pros.24090.
Article
CAS
PubMed
Google Scholar
Maeda Y, Kawano Y, Wada Y, Yatsuda J, Motoshima T, Murakami Y, et al. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways. Oncol Rep. 2015;33(4):1844–50. https://doi.org/10.3892/or.2015.3800.
Article
CAS
PubMed
Google Scholar
Xi W, Liu L, Wang J, Xia Y, Bai Q, Xiong Y, et al. Enrichment of C5a-C5aR axis predicts poor postoperative prognosis of patients with clear cell renal cell carcinoma. Oncotarget. 2016;7(49):80925–34. https://doi.org/10.18632/oncotarget.13108.
Article
PubMed
PubMed Central
Google Scholar
Imamura T, Yamamoto-Ibusuki M, Sueta A, Kubo T, Irie A, Kikuchi K, et al. Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis. Breast Cancer. 2016;23(6):876–85. https://doi.org/10.1007/s12282-015-0654-3.
Article
PubMed
Google Scholar
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097.
Article
PubMed
PubMed Central
Google Scholar
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16. https://doi.org/10.1186/1745-6215-8-16.
Article
PubMed
PubMed Central
Google Scholar
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. https://doi.org/10.1007/s10654-010-9491-z.
Article
PubMed
Google Scholar
Guo RF, Riedemann NC, Ward PA. Role of C5a-C5aR interaction in sepsis. Shock. 2004;21(1):1–7. https://doi.org/10.1097/01.shk.0000105502.75189.5e.
Article
CAS
PubMed
Google Scholar
Tang M, Zhang K, Li Y, He QH, Li GQ, Zheng QY, et al. Mesenchymal stem cells alleviate acute kidney injury by down-regulating C5a/C5aR pathway activation. Int Urol Nephrol. 2018;50(8):1545–53. https://doi.org/10.1007/s11255-018-1844-7.
Article
CAS
PubMed
Google Scholar
Posch W, Vosper J, Noureen A, Zaderer V, Witting C, Bertacchi G, et al. C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2-infected primary human airway epithelia. J Allergy Clin Immunol. 2021;147(6):2083–2097.e2086.
Article
CAS
Google Scholar
Brandolini L, Grannonico M, Bianchini G, Colanardi A, Sebastiani P, Paladini A, et al. The novel C5aR antagonist DF3016A protects neurons against ischemic Neuroinflammatory injury. Neurotox Res. 2019;36(1):163–74. https://doi.org/10.1007/s12640-019-00026-w.
Article
CAS
PubMed
PubMed Central
Google Scholar
Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014;25(2):225–31. https://doi.org/10.1681/ASN.2013020143.
Article
CAS
PubMed
Google Scholar
Wang Z, Yu W, Qiang Y, Xu L, Ma F, Ding P, et al. LukS-PV inhibits hepatocellular carcinoma progression by Downregulating HDAC2 expression. Mol Ther Oncolytics. 2020;17:547–61. https://doi.org/10.1016/j.omto.2020.05.006.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen J, Sun ZH, Chen LY, Xu F, Zhao YP, Li GQ, et al. C5aR deficiency attenuates the breast cancer development via the p38/p21 axis. Aging (Albany NY). 2020;12(14):14285–99. https://doi.org/10.18632/aging.103468.
Article
CAS
Google Scholar
Zha H, Han X, Zhu Y, Yang F, Li Y, Li Q, et al. Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade. Oncoimmunology. 2017;6(10):e1349587. https://doi.org/10.1080/2162402X.2017.1349587.
Article
PubMed
PubMed Central
Google Scholar
Vadrevu SK, Chintala NK, Sharma SK, Sharma P, Cleveland C, Riediger L, et al. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res. 2014;74(13):3454–65. https://doi.org/10.1158/0008-5472.CAN-14-0157.
Article
CAS
PubMed
Google Scholar